• Biotechnology Assets said Oct. 30, 2026, it sees no need for corrective action over an auditor’s qualification concerning deferred tax assets.
• The qualification arose in the limited review of first-half 2026 consolidated financial statements.
• Management disputes the accounting interpretation, expecting to recover the assets through future taxable profits within the timeframe allowed by accounting rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotechnology Assets SA published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.